Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VAMP-3 CRISPR/Cas9 KO Plasmid (h): sc-402306
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VAMP-3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the VAMP-3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VAMP-3 Antibody (E-10): sc-514843
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VAMP-3 CRISPR/Cas9 KO Plasmid (h) | sc-402306 | 20 µg | $397.00 |
Overview
VAMP3 encodes vesicle-associated membrane protein 3 (VAMP-3), a v-SNARE that mediates membrane fusion events required for constitutive and regulated exocytosis. It participates in vesicular trafficking between recycling endosomes and the plasma membrane, supporting receptor recycling, cytokine secretion, and delivery of membrane proteins during cell migration and polarization. VAMP-3 function intersects with endosomal sorting and SNARE-complex assembly pathways that shape immune cell activation and host–pathogen interactions. Dysregulated vesicle trafficking involving VAMP3 has been studied in contexts such as inflammation, altered glucose transporter dynamics, and cancer-associated changes in membrane turnover and invasion.
VAMP-3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the VAMP3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the VAMP3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the VAMP3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish VAMP-3 protein expression.
This CRISPR knockout system enables efficient generation of VAMP3-deficient cell models for investigation of VAMP-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting VAMP3 exon(s) critical for VAMP-3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple VAMP3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by VAMP-3 CRISPR/Cas9 KO Plasmid (h) and VAMP-3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the VAMP3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by VAMP-3 HDR Plasmid (h) and VAMP-3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by VAMP3 homology arms to support homology-directed repair at defined VAMP3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.